KRRO · CIK 1703647
What Korro Bio, Inc. told the SEC could break it.
Korro is a clinical-stage RNA-editing biotech with no product revenue expected for years: its only revenue is collaboration revenue from its Novo Nordisk agreement ($6.4 million in 2025), it has recurring net losses (including a $30.9 million lease impairment in Q4 2025), and its ability to continue depends on raising further capital. Its commercial future hinges on FDA acceptance of its INDs and approval of its candidates, and on adequate Medicare, Medicaid and commercial reimbursement — with drug-pricing measures like the IRA potentially pressuring economics. It also sources certain manufacturing materials from China and other countries, so tariffs, geopolitical events or pandemics could disrupt that supply and raise its early-stage costs.
3 self-disclosed vulnerabilities, pulled from its own filings — each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Regulatory & policy
- FDA approval (IND/clinical trials) and drug pricing/reimbursementmedium
Korro's commercialization depends on FDA acceptance of INDs and approval of its RNA-editing candidates, and on adequate Medicare/Medicaid/commercial reimbursement; drug-pricing measures (IRA/Medicaid rebate changes) could pressure future product economics.
“Adequate coverage and reimbursement from governmental healthcare programs, such as Medicare and Medicaid, and commercial payors is critical to new product acceptan”
- China-sourced manufacturing materials and tariff/supply-chain disruptionmedium
Korro sources certain manufacturing materials from China and other non-US countries; tariffs, geopolitical events or pandemics could disrupt that supply and raise its early-stage cost of goods.
“we source certain materials used in the manufacture of our products from China and other countries outside of the United States; supply chain disruptions (including as a result of announced tariffs, other geopolitical events or global health pandemics) could impact our business.”
Other disclosures
- clinical-stage, pre-revenue; collaboration revenue (Novo Nordisk) the only revenue; impairmentmedium
Korro has no product revenue and doesn't expect any for years; its only revenue is collaboration revenue from its Novo Nordisk agreement ($6.4M in 2025), it has recurring net losses (and a $30.9M Q4 2025 lease impairment), and going-concern depends on raising further capital.
“We have not generated any revenue from product sales, and do not expect to generate any revenue from the sale of products in the near future. During the year ended December 31, 2025 and 2024, we recognized $6.4 million and $2.3 million of collaboration revenue, respectively, which is related to our research collaboration and license agreement with Novo Nordisk.”
SEC filing →As of 2026
The hidden graph
Who it depends on, and who depends on it.
Relationships surfaced from filings — including ones disclosed by the other side, which is how the non-obvious ones come to light.
Its customers
“During the year ended December 31, 2025 and 2024, we recognized $6.4 million and $2.3 million of collaboration revenue, respectively, which is related to our research collaboration and license agreement with Novo Nordisk.”
Cited →
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch